Close Menu

Trovagene

Trovagene said this week that Charles Cantor has joined the company's scientific advisory board.

Trovagene has launched a noninvasive next-gen sequencing-based test that assesses seven known mutations in the KRAS gene.

Trovagene has appointed Charles Cantor to its scientific advisory board. Cantor is a professor emeritus of biomedical engineering and of pharmacology and was the director of the Center for Advanced Biotechnology at Boston University.

NEW YORK (GenomeWeb News) – Trovagene today announced a partnership with Catholic Health Initiatives Center for Translational Research (CTR) to evaluate the effectiveness of Trovagene's cell-free DNA cancer monitoring diagnostics in clinical practice.

NEW YORK (GenomeWeb News) – Trovagene reported after the close of the market on Monday a 71 percent drop in revenues for its fourth quarter.

Trovagene said this week that Rodney Markin has joined the company's board of directors.

David Flannery, a pediatric geneticist, is the new medical director of the American College of Medical Genetics and Genomics.

Cornell Research Foundation has been awarded

NEW YORK (GenomeWeb News) – Trovagene and US Oncology Research today announced a deal for the use of Trovagene's technology to determine whether KRAS mutations can be evaluated in urine to monitor pancreatic cancer patients.

NEW YORK (GenomeWeb News) – Trovagene reported after the close of the market Thursday that its third quarter revenues fell to $44,000 from $211,000 year over year.

Pages

AstraZeneca has released its coronavirus vaccine trial protocol, according to the New York Times.

Time magazine looks into how liquid biopsies are changing cancer care.

According to the Guardian, more than 150 countries have signed on to a global SARS-CoV-2 vaccine plan.

In PNAS this week: similar muscle protein patterns across hypertrophic cardiomyopathy phenotypes, analysis of gene expression and brain anatomy in major depression, and more.